Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 studyJacob P. Laubach, Paul G. Richardson, Mário Mariz et al.|The Lancet Oncology|2020Cited by 70